A 48-year-old man with treatment-resistant major depressive disorder is being evaluated for esketamine nasal spray (Spravato) after failing adequate trials of four antidepressant medications from different classes over the past three years. He has a current PHQ-9 score of 22, denies active suicidal ideation, and has no history of aneurysmal vascular disease, arteriovenous malformation, or intracerebral hemorrhage. His blood pressure today is 138/86 mmHg. He has no history of substance use disorder. The PMHNP is developing a treatment plan for esketamine initiation. Which of the following best describes the appropriate treatment planning considerations?